In Certain Types of Lung Cancer, Targeted Drug Tagrisso Slashed Recurrence Rates, New Study Says

Published Sep 22, 2020

In Certain Types of Lung Cancer, Targeted Drug Tagrisso Slashed Recurrence Rates, New Study Says

Already approved for EGFR-positive metastatic non-small cell lung cancer, osimertinib (Tagrisso ) brings major benefits in early cancer, too.

NOW
PLAYING
Remembering 'The King and I' Oscar Winner Yul Brynner
NOW
PLAYING
My Bladder Cancer Has Spread. What Are My Options?
NOW
PLAYING
Philanthropist John Ingram Had His Prostate Removed To Prevent Cancer
NOW
PLAYING
Dallas Cowboys Quarterback Dak Prescott Overcomes Grief of Mother’s Cancer Death, Losing Brother to Suicide & Ankle Injury, Makes Triumphant Return to Football
NOW
PLAYING
Immunotherapy Saved Lung Cancer Survivor Oswald Peterson
NOW
PLAYING
Pfizer Issues Nationwide Recall of Anti-Smoking Drug Chantix
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.